A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies
about
Acalabrutinib (ACP-196): a selective second-generation BTK inhibitorSecond-generation inhibitors of Bruton tyrosine kinasePI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.New drug discovery approaches targeting recurrent mutations in chronic lymphocytic leukemia.Targeting B Cell Signaling in Chronic Lymphocytic Leukemia.Bruton's tyrosine kinase inhibitors in B-cell lymphoma: current experience and future perspectives.Learning from the failures of drug discovery in B-cell non-Hodgkin lymphomas and perspectives for the future: chronic lymphocytic leukemia and diffuse large B-cell lymphoma as two ends of a spectrum in drug development.Small Molecule Inhibitors in Chronic Lymphocytic Lymphoma and B Cell Non-Hodgkin Lymphoma.Breakthrough therapies in B-cell non-Hodgkin lymphoma.Targeting of B-cell receptor signalling in B-cell malignancies.From identification of the BTK kinase to effective management of leukemia.Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia.Genetic aberrations in small B-cell lymphomas and leukemias: molecular pathology, clinical relevance and therapeutic targets.Recent advances in therapy of chronic lymphocytic leukaemia.Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies.NF-κB signaling pathway and its potential as a target for therapy in lymphoid neoplasms.Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside.Recommendations for Clinical Trial Development in Mantle Cell Lymphoma.Current Treatment of Chronic Lymphocytic Leukemia.What Is Optimal Front-Line Therapy for Chronic Lymphocytic Leukemia in 2017?Mechanisms of Resistance to Targeted Therapies in Chronic Lymphocytic Leukemia.PI3K signaling in cancer: beyond AKT.Follicular lymphoma: State-of-the-art ICML workshop in Lugano 2015.Novel agents in mantle cell lymphoma.Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.Anti-tumor efficacy study of the Bruton's tyrosine kinase (BTK) inhibitor, ONO/GS-4059, in combination with the glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab (GA101) demonstrates superior in vivo efficacy compared to ONO/GS-4059Novel approaches to targeting MYD88 in Waldenström macroglobulinemia.Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of management.Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy.Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib.Long-term follow-up of patients with CLL treated with the selective Bruton's tyrosine kinase inhibitor ONO/GS-4059.Ibrutinib and its use in the treatment of chronic lymphocytic leukemia.Combination therapy with the type II anti-CD20 antibody obinutuzumab.Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia.Role of Bruton's tyrosine kinase in B cells and malignancies.Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL).Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors.Responses to the Selective Bruton's Tyrosine Kinase (BTK) Inhibitor Tirabrutinib (ONO/GS-4059) in Diffuse Large B-cell Lymphoma Cell Lines.Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses.
P2860
Q28066316-CF06E943-F125-412B-A2BD-72C205BA0216Q28076118-1B6A2B42-3F87-4666-ABA1-77E6990C413CQ36274292-BC60F2E0-AB11-4C59-9C42-4AA78B05B440Q38646974-0D8CDF93-1BFB-4F39-80F9-8F0A5B253FEEQ38654101-5378DBDA-C943-466A-8840-84C3F656D4C3Q38665207-279075E4-C5F9-4854-B75B-2E4F6946643DQ38685006-BC8C52E8-CEE3-46CD-AD1D-B1F6D7B4DD08Q38691282-528EA712-62BE-4AC8-A6E7-444002ACA506Q38708600-37DDDA15-5E13-4B6F-954C-74F6202BD137Q38744922-057F12BF-8A36-4009-A69F-D410321ACBB0Q38817591-2C552ADE-CC78-4CD5-B9D3-096500C50474Q38818283-0469B91E-2AB7-43D9-9D6F-B2387479DBECQ38819164-E0CF00A9-C7AA-4AD3-8492-791AAECF5CA1Q38862525-89144DDF-6C6D-45CD-B13E-CB4ED5F59D1AQ38969861-D60632F9-FFBA-4749-915E-AE82795DD029Q38988815-5436195C-4165-48C9-A21E-E5934F1B2D88Q38989496-9B0356F1-04CE-4072-B216-E300FF8908BAQ39045701-8715FC86-B622-4185-9055-2A0C1D75E6C5Q39129372-4BD9E84B-256A-4908-86A7-4DF1A9703CB6Q39154057-DA7E158C-1D8F-4D42-AD22-F6294EB95B18Q39169789-923498BA-1BC7-40B2-A737-C5317D1F1652Q39200710-B26B09E0-72CE-4651-B417-F0BB57B2C55AQ39221094-A3DDE084-FEDA-43EB-9DAD-2AC46AF4F16BQ39290199-56FF53B7-65A5-4D2B-AEFC-E8EAAF12FC4DQ39325783-1E3649DD-E154-4317-B9C1-59F5ECCE27AAQ39339730-4FDCCE4B-7F52-4B18-95A8-6353C10324E3Q39375290-4CAFEF4E-4813-4EFE-BC39-62AAD5B888A7Q39383524-406B9D46-EC95-4314-9DAE-544DA4B19AE7Q39433250-CAFC152F-5F68-42A7-ADBF-91164A4DFBC3Q40144297-497073E4-9D8D-4101-AFEB-496E0589D550Q42318090-CB09765E-F8C2-4751-9C32-4D10E9FA3E4FQ42348711-B3768D8B-F912-4788-9424-A548A06147A2Q47780043-9E8C10C2-468E-449E-AB83-3410280711CAQ47898168-391567E1-1F0E-4F01-A66A-4932A7B6B2BCQ47932240-2E91957F-EA98-40F8-88DF-FE5E26D2C810Q49888075-A8EF081B-3B0A-432B-A46E-EE5BD768F092Q50072188-A51F234F-E13D-4621-BBB8-F54491F26186Q50121608-3EF4285D-4B8E-40B8-8089-6DEE35024AFDQ53691981-D6988DC6-BE40-4610-8BBF-3182E4118DF9Q53963822-71DD17F1-8F9E-4385-A0B6-6BA86C0A8C97
P2860
A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
A phase 1 clinical trial of th ...... ory mature B-cell malignancies
@ast
A phase 1 clinical trial of th ...... ory mature B-cell malignancies
@en
type
label
A phase 1 clinical trial of th ...... ory mature B-cell malignancies
@ast
A phase 1 clinical trial of th ...... ory mature B-cell malignancies
@en
prefLabel
A phase 1 clinical trial of th ...... ory mature B-cell malignancies
@ast
A phase 1 clinical trial of th ...... ory mature B-cell malignancies
@en
P2093
P2860
P50
P1433
P1476
A phase 1 clinical trial of th ...... ory mature B-cell malignancies
@en
P2093
Akihisa Nishimura
Bruno Cazin
Ceri Jones
Christopher Fegan
Claire V Hutchinson
Franck Morschhauser
Hideyuki Honda
John Sharpe
Joseph Birkett
Kevin Duffy
P2860
P304
P356
10.1182/BLOOD-2015-08-664086
P407
P577
2015-11-05T00:00:00Z